BTAX (Biostax) Cyclically Adjusted PB Ratio: (As of Jul. 27, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Biostax Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Biostax  (OTCPK:BTAX) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Biostax Cyclically Adjusted PB Ratio Related Terms


Biostax Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Biostax's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Biostax Cyclically Adjusted PB Ratio Chart

Biostax Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.06 0.02 0.00

Biostax Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.00 0.00 0.00 0.00

BTAX vs TRVN, HSTC, SYRS: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Biostax's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biostax Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biostax's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Biostax's Cyclically Adjusted PB Ratio falls into.



Biostax Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Biostax's Cyclically Adjusted Book per Share for the quarter that ended in Sep. 2024 is calculated as:

For example, Biostax's adjusted Book Value per Share data for the three months ended in Sep. 2024 was:

Adj_Book=Book Value per Share/CPI of Sep. 2024 (Change)*Current CPI (Sep. 2024)
=-0.063/315.3010*315.3010
=-0.063

Current CPI (Sep. 2024) = 315.3010.

Biostax Quarterly Data

Book Value per Share CPI Adj_Book
201412 13.030 234.812 17.496
201503 8.421 236.119 11.245
201506 5.886 238.638 7.777
201509 4.331 237.945 5.739
201512 -22.046 236.525 -29.389
201603 -19.712 238.132 -26.100
201606 -21.832 241.018 -28.561
201609 -22.047 241.428 -28.793
201612 -20.536 241.432 -26.819
201703 -22.489 243.801 -29.084
201706 -10.808 244.955 -13.912
201709 -10.863 246.819 -13.877
201712 -16.783 246.524 -21.465
201803 -16.485 249.554 -20.828
201806 -24.078 251.989 -30.128
201809 -25.767 252.439 -32.183
201812 -25.924 251.233 -32.535
201903 -25.779 254.202 -31.975
201906 -27.476 256.143 -33.822
201909 -29.542 256.759 -36.278
201912 -29.889 256.974 -36.673
202003 -31.618 258.115 -38.623
202006 -33.373 257.797 -40.817
202009 -24.434 260.280 -29.599
202012 -24.459 260.474 -29.607
202103 -22.290 264.877 -26.533
202106 -22.525 271.696 -26.140
202109 -16.066 274.310 -18.467
202112 -16.421 278.802 -18.571
202203 -21.705 287.504 -23.804
202206 -0.323 296.311 -0.344
202209 -0.032 296.808 -0.034
202212 -0.030 296.797 -0.032
202303 -0.033 301.836 -0.034
202306 -0.037 305.109 -0.038
202309 -0.042 307.789 -0.043
202312 -0.054 306.746 -0.056
202403 -0.058 312.332 -0.059
202406 -0.063 314.175 -0.063
202409 -0.063 315.301 -0.063

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Biostax Business Description

Address 2431 Aloma Avenue, Suite 124, Winter Park, FL, USA, 32792
Biostax Corp is a biotechnology company utilizing the Biostax Development Engine, is a developer and marketer of pharmaceutical, biotechnology and MedTech products that have a well-defined path to market. The company is focused on driving the development and commercialization of proprietary mechanisms to prevent, intercept and improve these diseases at affordable cost. It is a therapeutic and health tech agnostic, constantly seeking assets with low acquisition costs and high growth opportunities having significant clinical and commercial potential.